Problems Facing Monoclonal Antibody Technology

Abstract

Monoclonal antibodies (MABs), which are generated by B cells with precise specificity and strong affinity, have been widely recognized and praised by patients suffering from cancer and immune system disorders, as well as healthcare researchers, since their inception in 1972. These antibodies have been lauded for their exceptional specificity and facile recognition capabilities, which have made them indispensable in the treatment of a wide range of diseases. They are designed to bind to specific antigens, allowing for a more precise treatment, reducing the risk of damage to healthy cells and tissues. Despite their pivotal role in disease treatment, monoclonal antibodies are not without their challenges. One of the most significant issues is their exorbitant cost, which can make these treatments inaccessible for many patients. Additionally, there are potential adverse effects associated with their use, including allergic reactions and immune system complications. Ethical concerns have also been raised, particularly in relation to the use of animals in the production of these antibodies. Another major challenge is the emergence of drug resistance. Over time, some diseases can become resistant to the effects of monoclonal antibodies, reducing their efficacy. This is a significant issue, particularly in the treatment of diseases such as cancer, where the development of resistance can have serious implications for patient outcomes. Despite these challenges, the potential of monoclonal antibodies in disease treatment is undeniable. Ongoing research is focused on addressing these issues, with efforts being made to reduce costs, minimize adverse effects, address ethical concerns, and combat drug resistance.